Reference is made to Aker BioMarine ASA's (the "Company") stock exchange
announcement earlier today regarding the offer of new shares to employees in the
Company and its Norwegian subsidiaries (the "Employee Share Purchase Program")
and the board of directors' resolution to increase the share capital of the
Company. 

The following primary insiders of the Company have applied for, been allocated
and subscribed new shares in the Company at the offer price of NOK 83,01 per
share in the Employee Share Purchase Program.

-	Matts Johansen, CEO, has subscribed for 939 new shares in the Company for a
total subscription amount of NOK 77 942. Following the subscription, Johansen
controls 1,126,776 shares in the Company.

-	Simon Seward, CEO Human Ingredients, has subscribed for 939 new shares in the
Company for a total subscription amount of NOK 77 942. Following the
subscription, Seward controls 4,722 shares in the Company.

-	Bilal Ahmad, Board Director, has subscribed for has subscribed for 939 new
shares in the Company for a total subscription amount of NOK 77 942. Following
the subscription, Ahmad controls 2369 shares in the Company.

-	Trond Atle Smedsrud, CEO Emerging Business, has subscribed for 939 new shares
in the Company for a total subscription amount of NOK 77 942. Following the
subscription, Smedsrud controls 12,228 shares in the Company.

-	Anniken Færgestad, VP Finance, has subscribed for 939 new shares in the
Company for a total subscription amount of NOK 77 942. Following the
subscription, Færgestad controls 3,428 shares in the Company.

-	Lars Jacobsen, General Counsel, has subscribed for 939 new shares in the
Company for a total subscription amount of NOK 77 942. Following the
subscription, Jacobsen controls 4,412 shares in the Company.

-	Kristin Holmgren, Board Director, has subscribed for 301 shares in the Company
for a total subscription amount of NOK 24 984. Following the subscription,
Holmgren controls 4,647 shares in the Company.

Attached to this announcement is supplementary information regarding primary
insiders' share subscriptions.

For further information, please contact 
Lars Jacobsen, General Counsel 
Mobile: +47 906 05 306 
Email: lars.jacobsen@akerbiomarine.com

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.

About Aker BioMarine:
Aker BioMarine is a leading human health and nutrition innovator that develops
krill-derived products for consumer health and nutrition. Krill is a natural,
powerful, and health-promoting source of nutrients from the pristine waters of
Antarctica, and Aker BioMarine has a unique position in its industry. The
ingredient portfolio consists of Superba Krill Oil, Lysoveta, Revervia, and PL+,
as well as the consumer brand, Kori Krill. The innovative approach also extends
into the spin-offs AION (reduce and recycle plastic waste across industries) and
Understory (a protein brand). Aker BioMarine is listed on the Oslo Stock
Exchange (AKBM). More information is available at www.akerbiomarine.com.